encorafenib

Drug Overview

Encorafenib is a highly specialized “Smart Drug” used to treat specific types of advanced cancers. It belongs to a group of medications called Targeted Therapy. Unlike traditional chemotherapy, which affects all fast-growing cells, encorafenib is designed to find and block a specific mutated protein that causes cancer cells to grow out of control.

• Generic Name: Encorafenib
• US Brand Names: Braftovi®
• Drug Class: BRAF Kinase Inhibitor
• Route of Administration: Oral (Capsules taken by mouth)
• FDA Approval Status: FDA-approved for specific types of Melanoma and Colorectal Cancer.
  
  Discover the therapeutic potential of encorafenib. Our research-driven hospital delivers exceptional patient support and expert guidance for oncology.

What Is It and How Does It Work? (Mechanism of Action)

Encorafenib works by interrupting the internal “instruction manual” of a cancer cell. To understand how it works, we must look at a signaling pathway inside the cell called the MAPK pathway. This pathway acts like a series of switches that tell the cell when to divide and grow.

Molecular Level Activity

In many cancers, a specific gene called BRAF develops a mutation, most commonly the V600E or V600K mutation. This mutation causes the BRAF protein to become stuck in the “ON” position. As a result, the cell receives a constant, unstoppable signal to multiply, leading to tumor formation.

Encorafenib is a competitive ATP-inhibitor. It travels into the cancer cell and binds specifically to the mutated BRAF kinase. By “plugging” into this protein, encorafenib:

1. Shuts off the switch: It prevents the mutated BRAF from activating the next protein in the chain (MEK).
2. Halts growth: Without the signal moving down the pathway to the nucleus, the cell stops dividing.
3. Induces Cell Death: In many cases, the loss of these growth signals triggers the cancer cell to undergo apoptosis, or programmed cell death.

Encorafenib is uniquely designed to have a “long residence time,” meaning it stays attached to the mutated protein longer than many other drugs in its class, providing more consistent control over the cancer.

FDA Approved Clinical Indications

Encorafenib is specifically used for cancers that test positive for the BRAF^{V600E} or V600K mutation. It is typically used in combination with other medications to prevent the cancer from finding “detours” around the blocked pathway.

Oncological uses:

• Unresectable or Metastatic Melanoma: Used in combination with binimetinib (Mektovi®) for patients whose skin cancer has spread or cannot be removed by surgery.
• Metastatic Colorectal Cancer (CRC): Used in combination with cetuximab (Erbitux®) for adult patients who have already received previous treatments.

Non-oncological uses:

• There are currently no FDA-approved non-oncological uses for this medication.

Dosage and Administration Protocols

The dosage of encorafenib depends on the type of cancer being treated. It is vital that the medication is taken exactly as prescribed, usually once daily.

Dose Adjustments

• Hepatic Insufficiency: For patients with mild liver impairment, no adjustment is usually needed. For moderate to severe liver issues, the drug is used with caution as it is primarily processed by the liver.
• Renal Insufficiency: No dose adjustment is generally required for patients with mild to moderate kidney issues. Data is limited for patients with severe kidney disease.
• Side Effect Management: If severe side effects occur (such as heart or eye issues), the dose may be reduced to 300 mg or 225 mg, or paused entirely.

Clinical Efficacy and Research Results

Recent clinical data (2020–2025) has confirmed that encorafenib significantly improves survival when used in combination therapies.

• Melanoma (COLUMBUS Trial): Research showed that patients taking the combination of encorafenib and binimetinib had a median Progression-Free Survival (PFS) of 14.9 months, compared to only 7.3 months for those on older single-drug therapies.
• Colorectal Cancer (BEACON CRC Trial): In patients with the BRAF^{V600E} mutation, the combination of encorafenib and cetuximab showed a Median Overall Survival (OS) of 9.3 months, compared to 5.9 months for standard chemotherapy. This trial was a landmark study that led to a new standard of care for this specific patient group.
• Overall Response: In recent updates, the objective response rate (tumor shrinkage) was significantly higher in targeted therapy groups than in traditional chemotherapy groups for both melanoma and colorectal cancer.

Safety Profile and Side Effects

Encorafenib is generally well-tolerated, but because it interferes with cell signaling, it can cause various side effects.

Black Box Warning:

Encorafenib does not currently carry a “Black Box Warning.” However, it is known to increase the risk of developing new skin cancers (such as squamous cell carcinoma), which are usually easily treated.

Common Side Effects (>10%)

• Fatigue: Feeling unusually tired or weak.
• Nausea and Diarrhea: General stomach upset.
• Arthralgia: Joint pain or swelling.
• Skin Rash: Including dryness, itching, or thickening of the skin.
• Abdominal Pain: Discomfort in the stomach area.

Serious Adverse Events

• New Malignancies: Development of new skin or non-skin cancers.
• Uveitis: Inflammation of the eye causing redness or blurred vision.
• QT Prolongation: Changes in the heart’s electrical rhythm.
• Hepatotoxicity: Liver stress indicated by abnormal blood tests.

Management Strategies:

• Skin Checks: Patients should see a dermatologist every 2 months during treatment.
• Eye Issues: If blurred vision or light sensitivity occurs, an immediate eye exam is required.
• Hydration: Drinking plenty of fluids can help manage kidney stress and fatigue.

Research Areas

Current research into encorafenib is exploring its use in “triple combinations” and its role in earlier stages of cancer. Scientists are investigating how combining encorafenib with Immunotherapy (such as PD-1 inhibitors) might “prime” the immune system to recognize cancer more effectively. Other studies are looking into whether this targeted approach can be used after surgery (adjuvant therapy) to prevent the cancer from returning.

Patient Management and Practical Recommendations

Pre-treatment Tests

• BRAF Mutation Test: You must have a confirmed BRAF^{V600E} or V600K mutation via an FDA-approved test before starting.
• Liver and Kidney Function: Baseline blood work to ensure organs are healthy.
• EKG: To check the heart’s electrical rhythm (QT interval).
• Skin Exam: A full-body check for existing lesions.

Precautions During Treatment

• Sun Sensitivity: Encorafenib makes your skin more sensitive to sunlight. Use SPF 30+ and wear protective clothing.
• Birth Control: Both men and women should use effective non-hormonal birth control during treatment and for at least 2 weeks after the last dose, as the drug can harm a developing fetus.

“Do’s and Don’ts”

• DO take the capsules at the same time every day.
• DO swallow capsules whole; do not crush or dissolve them.
• DON’T eat grapefruit or drink grapefruit juice, as it can dangerously increase the drug levels in your blood.
• DON’T ignore new skin growths, moles, or changes in vision.

Legal Disclaimer

This guide is for informational purposes only and does not replace professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read in this guide.